Natural Human HMW Kininogen protein (ab90353)

Overview

  • Product nameNatural Human HMW Kininogen protein
  • Protein lengthFull length protein

Description

  • NatureNatural
  • SourceNative
  • Amino Acid Sequence
    • SpeciesHuman

Specifications

Our Abpromise guarantee covers the use of ab90353 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    SDS-PAGE

  • Purity> 95 % SDS-PAGE.

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -20ºC. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 250mM Sodium chloride, 10mM Sodium acetate, pH 5.5

General Info

  • Alternative names
    • Alpha 2 thiol proteinase inhibitor
    • Alpha-2-thiol proteinase inhibitor
    • BDK
    • BK
    • Bradykinin
    • Fitzgerald factor
    • High molecular weight kininogen
    • HMWK
    • Ile-Ser-Bradykinin
    • Kallidin I
    • Kallidin II
    • Kininogen 1
    • KNG
    • KNG1
    • KNG1_HUMAN
    • Low molecular weight growth-promoting factor
    • Williams-Fitzgerald-Flaujeac factor
    see all
  • Function(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
  • Tissue specificitySecreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
  • Involvement in diseaseDefects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
  • Sequence similaritiesContains 3 cystatin domains.
  • Post-translational
    modifications
    Bradykinin is released from kininogen by plasma kallikrein.
    Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
    Phosphorylation sites are present in the extracelllular medium.
    N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
  • Cellular localizationSecreted > extracellular space.
  • Information by UniProt

References for Natural Human HMW Kininogen protein (ab90353)

ab90353 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab90353.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"